Recent clinical trial results signal progress in cancer immunotherapy and chemotherapy alternatives. Novartis’ monoclonal antibody ianalumab achieved two Phase 3 wins in autoimmune disorders, including Sjögren’s syndrome and immune thrombocytopenia. In bladder cancer, Pfizer’s antibody-drug conjugate Padcev combined with Keytruda improved survival outcomes in patients ineligible for cisplatin chemotherapy. Separately, transformative chemotherapy-free regimens using venetoclax combined with targeted and immune therapies advance treatment of acute myeloid leukemia, particularly for elderly or unfit patients with IDH mutations.